Glaukos (GKOS) Q2 Revenue Jumps 30%

Glaukos (GKOS) announced robust Q2 2025 results, with GAAP revenue of $124.1 million, a 29.7% year-over-year increase, significantly surpassing estimates, and non-GAAP EPS of ($0.24) beating expectations while nearly halving prior year losses. This strong performance, primarily driven by the rapid uptake and expanding reimbursement of its iDose TR implant, led the company to raise its 2025 net sales guidance to $480-$486 million. Despite ongoing operating losses, Glaukos maintains a strong balance sheet, with investors now focused on iDose TR's commercial trajectory and the anticipated October FDA decision for its Epioxa therapy.

Analysis

Glaukos (GKOS) reported a robust second quarter for 2025, demonstrating significant operational momentum driven by its new product pipeline. The company delivered a strong top- and bottom-line beat, with GAAP revenue of $124.1 million, a 29.7% year-over-year increase that surpassed analyst estimates by 7.4%. The non-GAAP EPS loss of ($0.24) was narrower than the anticipated ($0.26) and represented a 53.8% improvement from the prior year, indicating progress toward profitability. The primary growth catalyst was the glaucoma franchise, where sales climbed 36%, led by a 45% surge in U.S. net sales. This performance is directly attributable to the rapid commercial uptake of the iDose TR implant, which is benefiting from expanding reimbursement coverage. Consequently, management raised its full-year 2025 revenue guidance to a range of $480-$486 million. However, this growth is capital-intensive, reflected in a 27% increase in non-GAAP SG&A expenses and guidance for 15% overall operating expense growth. Furthermore, the company faces headwinds in its legacy portfolio, with U.S. stent revenue projected to decline in the mid-single digits due to reimbursement restrictions and its corneal health product line remaining stagnant. The company maintains a strong balance sheet with $278.6 million in cash and no debt, providing a solid foundation to fund its growth initiatives and navigate the upcoming FDA decision for its Epioxa therapy in October 2025.

Key Decisions for Investors

• The strong beat-and-raise quarter validates the growth thesis centered on iDose TR, and investors should prioritize tracking its adoption rates and expanding reimbursement wins as the primary value driver.
• Position for a key catalyst with the upcoming FDA decision on Epioxa expected by October 2025, as an approval would provide a significant new revenue stream and diversify the product portfolio beyond glaucoma.
• While revenue growth is accelerating, it is critical to scrutinize the path to profitability by monitoring the guided 15% increase in operating expenses against the backdrop of reimbursement headwinds impacting legacy product lines.
• Given the company's strong balance sheet with no debt, investors should assess management's capital allocation strategy, particularly the return on increased SG&A and R&D spending.